Clinical Trial Update: Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating camrelizumab plus apatinib and tegio in first-line refractory patients with advanced gastric cancer; efficacy and saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab for Injection (camrelizumab)
• Tegio

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN